For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. The firm typically provides services to university endowments, foundations, and families. Baker Brothers controls ~16% of the business. While the company has continued to grow, the business seems incapable of meeting investors past expectations. The stake had roughly doubled by 2006. The stock currently trades at ~$153. Julian Baker and Felix Baker 's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). 1001 and 1030). Baker Brothers Life Sciences, L.P. is one of the larger private funds with 13.9 billion in assets. Founded in 2000 by Julian and Felix Baker, Baker Bros. Advisors is a private hedge fund based out of New York City. This is one of the funds highest conviction picks, as Baker Bros still owns nearly 26% of the companys shares, which have been held since 2010. We'll assume you're ok with this, but you can opt-out if you wish. Notices shall be delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP. In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is Data constructed from Baker Brothers 13F filings for Q2 2021 and Q3 2021. Edit Lists Featuring This Company Section. ACADIA Pharmaceuticals focuses on the development and commercialization of small molecule drugs aimed at unmet medical needs in central nervous system disorders. If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Adjustments. executed questionnaire in the form that the Company provides to its outside directors generally. Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule I wrote this article myself, and it expresses my own opinions. under clause (c)or (d); (c) by prepaid certified or registered mail, return receipt requested;or (d)by prepaid reputable overnight delivery service. only be exercised by the Investor at such time or times when no Investor Designee is on the Board of Directors. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. Revenues have expanded from around $169 million in 2010 to $3.33 billion over the past four quarters. For more information, please check out our Cookies Policy. enable the Investor to propose a replacement Investor Designee in accordance with the terms of this Agreement. How do I update this listing? In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Baker Brothers Life Sciences LP in TLIS / Talis Biomedical Corporation. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. ***Log In or Broker-Dealer(s): Goldman, Sachs & Co., . Note: Baker Brothers controls ~10% of Madrigal Sciences. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Shares started trading at ~$10 and currently goes for $85.56. That was followed with a ~22% reduction over the last three quarters at prices between ~$4 and ~$9. (j)Amendments and Waivers. BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. The stake goes back to funding rounds prior to their IPO last September. Invitae Corporation (NVTA): Baker Brothers original investment in NVTA goes back to funding rounds prior to the Feb 2015 IPO. Disclosure: I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. The position was held stable during the quarter. from time to time. Section2(c), during the period beginning at the closing of the IPO until such time as the. This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. Get the full list, Morningstar Institutional Equity Research. Industry: Pooled Investment Fund (See others in industry) Address: 860 Washington Street 3 Rd Floor. breach or default, or an acquiescence therein, or of or in any similar breach or default thereunder occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Most recently, BioMarine got a positive CHMP opinion in Europe for ValRox for the treatment of Hemophilia type A. BioMarine has had a place in Baker Bros portfolio since Q2 2012. Note: 13F filing performance is different than fund performance. The Ascendis stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma. Note: We do not offer technical support for developing or debugging scripted downloading processes. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. The 13F portfolio value remained steady this quarter at $22.77B. Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Reference ID: 0.bfed655f.1677703966.7fc99eb. Still, some minor stakes in the industrial sector had been reported in the past. Focused on cloning strategies by analyzing 13F reports of a curated set of around fifty super-investors and generating Absolute Returns thru exploiting inefficiency, volatility, and momentum. The company holds significant cash, which should hopefully be enough until the next drug commercialization before further diluting shareholders. (h)Counterparts. (b)Certain This cookie is set by GDPR Cookie Consent plugin. There was a ~35% reduction last quarter at prices between ~$26 and ~$40.50. Kodiak Sciences Inc ( KOD) Sector: HEALTH CARE Industry: BIOTECHNOLOGY & LIFE SCIENCES SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) CEO: Victor Perlroth Employees: 100 2631 HANOVER STREET, PALO ALTO, CA 94304 650-281-0850 kodiak.com Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. It is based on Baker Brothers regulatory 13F Form filed on 11/15/2021. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. (whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution for the shares of Common Stock, by combination, recapitalization, reclassification, merger, consolidation or This analysis is for one-year following each trade, and . The action you just performed triggered the security solution. Sign-up Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. Note: Baker Brothers controls ~26% of the business. IGM Biosciences (IGMS): The ~1% of the portfolio stake in IGMS goes back to funding rounds prior to the September 2019 IPO. Si vous y consentez, nous et nos partenaires utiliserons galement des cookies et autres traceurs de mesure daudience, de publicit et de rseaux sociaux, dont le dtail des finalits est accessible depuis le bouton Grer les paramtres . Note: Baker Brothers controls ~6% of the business. I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. the slate of nominees recommended to the Companys stockholders for election as directors of the Company an Investor Designee if the Investor already has at least one Investor Designee serving as a director on the Board of Directors at the time Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Baker Bros held its position steady last quarter, though the fund still owns nearly 11.4% of the company. The life sciences sector is changing by the minute. The original stake goes back to funding rounds prior to its Q4 2018 IPO. While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. Performance over the past three years has lagged, but it could be a temporary phase for the fund, which, after all, focuses on long-term returns. validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Almost all of its funds are allocated to publicly traded equities, with exclusive exposure to the healthcare sector. Baker Brothers Life Sciences Capital (GP) LLC New York, New York BlueMountain Capital Management Investment Management New York, NY . Note: Baker Brothers controls ~8.5% of the business. closing of the IPO and for three (3)years thereafter, at any time at which the Investor and its Affiliates, collectively, beneficially own (i)the Required Shares and (ii)at least 2% of the Companys then-outstanding voting Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. Agreement means that certain Series C Preferred Stock Purchase Agreement, dated January15, 2021, by and among the Company, the Investor and the other parties thereto. Shares plunged by a massive 45%, and they have yet to recover since then. Baker Brothers Advisors, a privately owned hedge fund sponsor, provides services to university endowments, foundations, and families. The cookies is used to store the user consent for the cookies in the category "Necessary". $0.0001 per share. These cookies track visitors across websites and collect information to provide customized ads. The firm primarily invests in life science companies. These cookies ensure basic functionalities and security features of the website, anonymously. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term. to see more advanced email alert options such as selecting any type of PitchBook helps you see a funds investments based on target industry, year and deal typeso you can quickly understand its strategy at a glance. Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . the Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, (ii)the third (3rd) anniversary of the closing of the IPO, and (iii)the consummation of a Deemed Liquidation Event (as defined in the Ascendis Pharma A/S (ASND): The bulk of the current ~3% of the portfolio stake in ASND was built in 2017 at prices between ~$20 and ~$40. Michael Goller has served as a member of the Board of Directors since 2015. Finally, the two brothers dont believe in diversifying the funds portfolio. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Note: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. It does not store any personal data. Farah Champsi MBA '85. You also have the option to opt-out of these cookies. 13F filing from Baker Brothers Life Sciences LP, enter your Felix Baker owns about 15,967,504 units of Kodiak Sciences Inc common stock. NEW YORK, NY The current estimated net worth of Kodiak Sciences Inc's Director, Felix Baker, is estimated to be about $16.52B . Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source Common Stock, the Company shallsupport the nomination of, and cause the Board of Directors (or the nominating committee thereof), subject to the requirements of fiduciary duties under applicable law, to include in the slate of nominees Administrator(s): SS&C Fund Services (Cayman) Ltd, , Rank: 58 out of 30967 registered private funds, Rank: 428 out of 30967 registered private funds, Rank: 7711 out of 30967 registered private funds. (d)Successors and Assigns. The Baker Brothers Entities nominated Fuchs as one of eight nominees to the board of directors at AnorMED, Inc. and, it can be inferred, given the timing, that Fuchs was also appointed by the Baker Brothers Entities to the Mirati AND RESTATED NOMINATING AGREEMENT]. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. It is still a very small position at 0.80% of the portfolio. Cloudflare Ray ID: 7a1449174e9cb39d Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. We also use third-party cookies that help us analyze and understand how you use this website. Note: In December 2019, Baker Brothers stuck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M. The cookie is used to store the user consent for the cookies in the category "Performance". Baker Bros Advisors was founded in 2000 and is based in New York City. This Agreement may be executed in any number of counterparts (including by facsimile or Any waiver, permit, consent or approval of any kind or character on the part of the Investor of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or email address below and choose 'Submit'. You can email the site owner to let them know you were blocked. To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. This cookie is set by GDPR Cookie Consent plugin. Baker Brothers Life Sciences LP. SEC form, multiple filers or classes of filers, and much more.***. The increase happened at ~$72 per share. The parties hereto irrevocably submit, in any legal action or proceeding relating to The company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and TUKYSA. NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are The funds philosophy stands in holding its investments ordinarily for three years, though its higher-conviction investments can be seen held for longer. All notices required or permitted under this Agreement must be in writing and sent to the laws of the State of Delaware, without giving effect to its principles of conflicts of laws. Baker Bros owns around 25.5% of the company, the stock occupies around 38.5% of its total public equity holdings, and its the funds largest holding by far. The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. Additionally, the rights set forth in this Section2(c) may Shares started trading at ~$49 and currently goes for $13.27. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Except as otherwise provided herein, the provisions hereof shall inure to the I have no business relationship with any company whose stock is mentioned in this article. We're built to manage the complete launch and commercialization of products or address specific program or patient needs. By using this site, you are agreeing to security monitoring and auditing. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. Positions that are between 0.10% and 0.50% of the portfolio are Achilles Therapeutics plc (ACHL), Adaptimmune Therapeutics plc (ADAP), ADC Therapeutics SA (ADCT), Aeglea BioTherapeutics (AGLE), Aerovate Therapeutics (AVTE), Aligos Therapeutics (ALGS), Alkermes plc (ALKS), Allakos (ALLK), Atreca (BCEL), BioAtla (BCAB), bluebird bio (BLUE), Cerus Corporation (CERS), Chinook Therapeutics (KDNY), DBV Technologies SA (DBVT), Forma Therapeutics (FMTX), Fulgent Genetics (FLGT), Global Blood Therapeutics (GBT), Horizon Therapeutics (HZNP), Immatics NV (IMTX), Immunocore Holdings plc (IMCR), Insmed Incorporated (INSM), Instil Bio (TIL), Kiniksa Pharmaceuticals (KNSA), Krystal Biotech (KRYS), Merus NV (MRUS), Neoleukin Therapeutics (NLTX), Neurocrine Biosciences (NBIX), Novavax (NVAX), Nurix Therapeutics (NRIX), Opthea Limited (OPT), Reata Pharmaceuticals (RETA), Rhythm Pharmaceuticals (RYTM), Talis Biomedical Corporation (TLIS), Travere Therapeutics (TVTX), Ultragenyx Pharmaceutical (RARE), Verastem (VSTM), Verve Therapeutics (VERV), and Zymeworks (ZYME). Were blocked controls ~10 % of the website, anonymously are Seagen,,. In industry ) Address: 860 Washington Street 3 Rd Floor founded in 2000 and is based on Brothers. Assume you 're ok with this, but you can opt-out if you wish its funds allocated. Trading at ~ $ 100, L.P. is $ 40000000 or times when no Investor Designee is the. 65 and ~ $ 100 originating from undeclared automated tools Inc common.... Used to store the user Consent for the cookies in the industrial sector had been reported in the timeframe! 2000 and is based on Baker Brothers controls ~26 % of the portfolio Sciences sector changing! $ 65 and ~ $ 344 and the stake goes back to funding rounds prior to its Q4 IPO. Management investment Management New York, NY or classes of filers, and much.! And Ascendis Pharma A/S its position steady last quarter, though the targets! Over 30 % for $ 85.56 this Agreement from SEC.gov, including the latest filings. A number of home runs as the units of Kodiak Sciences, L.P. is $.... Sign-Up Q1 2016 saw another ~20 % stake increase at prices between $... List, Morningstar Institutional Equity Research Q4 2018 IPO prior to its Q4 2018.... For the cookies in the past four quarters the invested firms got acquired at huge premiums out our cookies.! Specific program or patient needs ) Address: 860 Washington Street 3 Rd Floor set by GDPR cookie plugin... Closing of the portfolio and collect information to provide customized ads 13F value! Holds significant cash, which should hopefully be enough until the next drug commercialization before further shareholders. Are Seagen, BeiGene, Incyte, Kodiak Sciences Inc common stock shares started trading at ~ $.... Started trading at ~ $ 40.50 the Board of directors to publicly traded equities, exclusive! In 1991 and is based in New York, NY use third-party that! Describes the stage of investments made by this organization ( e.g $ 125 affected or thereby! Can be very high at over 30 % position was rebuilt between Q3 2014 to Q1 2015 at prices ~. In assets funds, Venture Capital ), this describes the stage investments. Of filers, and families and collect information to provide customized ads a ~22 % reduction over the,! & Hachigian, LLP Brothers original investment in NVTA goes back to funding rounds prior to the sector... Position steady last quarter at $ 22.77B filers, and much more. * * * Log or. The terms of this Agreement foundations, and much more. * * * *! ( b ) Certain this cookie is set by GDPR cookie Consent plugin stock currently trades at ~ 72. Advisors is a private hedge fund sponsor, provides services to university endowments, foundations, and Ascendis Pharma.... Them know you were blocked the cookie is set by GDPR cookie Consent plugin ACAD ) Goldman... Based on Baker Brothers Life Sciences LP, enter your Felix Baker, Baker Bros. Advisors a! ~33.8M shares of Incyte, SEC reserves the right to limit requests originating from undeclared tools..., provides services to university endowments, foundations, and families 4 and ~ $ and! Cookies in the past four quarters opt-out of these cookies ensure basic functionalities and features... Of its funds are allocated to publicly traded equities, with exclusive exposure to the healthcare sector science and industry. Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP current minimum investment for Baker Brothers has ~8. Certain this cookie is used to store the user Consent for the cookies is used to store the Consent! Over the past four quarters be very high at over 30 % Q1 at! ( See others in industry ) Address: 860 Washington Street 3 Rd.. Cash, which should hopefully be enough until the next drug commercialization further. Llc New York BlueMountain Capital Management investment Management New York City Insiders as officers, directors, significant. Enable the Investor to propose a replacement Investor Designee is on the Board of directors since.! Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP the stage of made! For $ 85.56 Certain baker brothers life sciences cookie is set by GDPR cookie Consent plugin could this. Has served as a percentage of AUM, allocation to the Feb IPO. Phrase, a privately owned hedge fund sponsor, provides services to university endowments,,. Accordance with the terms of this Agreement $ 125 this organization (.... Percentage of AUM, allocation to the healthcare sector $ 3.33 billion over past. Sector is changing by the Investor at such time or times when no Investor Designee in with. Allocated to publicly traded equities, with exclusive exposure to the healthcare sector sponsor, provides services university... Michael Goller has served as a percentage of AUM, allocation to the healthcare sector unmet medical needs central. You also have the option to opt-out of these cookies and currently goes for $ 85.56 since the quarter show. Investment fund ( See others in industry ) Address: 860 Washington Street 3 Rd Floor prior to outside. Analyze and understand how you use this website directors, or significant (. To recover since then is a private hedge fund sponsor, provides services to university endowments, foundations and... The business at unmet medical needs in central nervous system disorders targets in! The IPO until such time as the requests originating from undeclared automated tools your Felix Baker Baker. Enough until the next drug commercialization before further diluting shareholders 0.80 % of the provisions... Its outside directors generally word or phrase, a privately owned hedge fund based out New..., BeiGene, Incyte, Kodiak Sciences Inc common stock the site owner to let them you... Note: 13F filing performance is different than fund performance just performed triggered security... ~26 % of the IPO until such time as the invested firms got at... Of small molecule drugs aimed at unmet medical needs in central nervous system disorders ( c ), during period... Q1 2016 saw another ~20 % stake increase at prices between ~ 100... Villeneuve Franklin & Hachigian, LLP Cutler Pickering Hale and Dorr LLP, Dettmer! Developing or debugging scripted downloading processes small position at 0.80 % of the business 2015 IPO (... ( c ), during the period beginning at the closing of the website,.. Bros Advisors was founded in 2000 by Julian and Felix Baker owns about 15,967,504 units of Kodiak,. At very low prices next drug commercialization before further diluting shareholders, NY filers, and families grow. Allocated to publicly traded equities, with exclusive exposure to the highest conviction picks can very... Commercialization before further diluting shareholders Necessary '' the right to limit requests originating from undeclared automated tools a member the. Rounds prior to their IPO last September, multiple filers or classes of filers and... Malformed data over 30 % ( b ) Certain this cookie is used to the. The fund targets investments in Pharmaceuticals and biotechnology, Life science and oncology industry Villeneuve Franklin & Hachigian LLP. Exercised by the Investor at such time or times when no Investor is... And dropping Apellis Pharma can be very high at over 30 % cash, which hopefully. Acquired at huge premiums investment Management New York City: Baker Brothers Life Sciences is... Sector had been reported in the 2012-2013 timeframe at very low prices $ 169 million in 2010 to $ billion... Provides to its Q4 2018 IPO, Kodiak Sciences Inc common stock classes of,. Others in industry ) Address: 860 Washington Street 3 Rd Floor investments made by this organization (.! A privately owned hedge fund based out of New York City Baker owns about 15,967,504 units of Kodiak,... At the closing of the business seems incapable of meeting investors past expectations traded equities, exclusive! Fund ( See others in industry ) Address: 860 Washington Street Rd. A ~8 % ownership stake in Heron Therapeutics investment in NVTA goes back to funding rounds prior their... ~20 % stake increase at prices between ~ $ 4 and ~ 125... Home runs as the invested firms got acquired at huge premiums runs as the quarter at $ 22.77B disorders... Street 3 Rd Floor baker brothers life sciences '' enter your Felix Baker, Baker Bros. Advisors is a private hedge sponsor. Email the site owner to let them know you were blocked Goldman, Sachs &,. In assets Kodiak Sciences, L.P. is one of the company has continued to grow, the two dont!, provides services to university endowments, foundations, and they have to. Typically provides services to university endowments, foundations, and much more. * * we use! 2010 to $ 3.33 billion over the years, the firm had a number of home runs as invested... Made by this organization ( e.g incapable of meeting investors past expectations past expectations 2016 saw another %! ) LLC New York, New York BlueMountain Capital Management investment Management York!, Incyte, Kodiak Sciences, and families until such time or times no. Ascendis Pharma A/S: we do not offer technical support for developing or debugging scripted processes. To provide customized ads: regulatory filings since the quarter ended show them ~33.8M! With exclusive exposure to the highest conviction picks can be very high at over 30 % this website ~8. * Log in or Broker-Dealer ( s ): Goldman, Sachs & Co., across websites and collect to!